VSTM — Verastem, Inc.

Summary of Verastem Oncology Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Product Revenue: $17.5 million for Q4 2025; $30.9 million for the full year (May-December 2025).
• Cost of Sales: $2.6 million for Q4; $4.6 million for the full year.
• R&D Expenses: $31.7 million for Q4; $114.6 million for the full year, driven by ongoing clinical trials.
• SG&A Expenses: $24.4 million for Q4; $81.1 million for the full year, primarily due to commercial activities.
• Non-GAAP Adjusted Net Loss: $39.8 million ($0.48 per share) for Q4; $163.1 million ($2.35 per share) for the full year.
• Cash Position: Ended Q4 with $205 million; pro forma cash balance of $234.4 million after warrant exercises, extending runway into H1 2027.

2. Strategic Updates and Business Highlights

• FDA Approval: Achieved FDA approval for AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) ahead of schedule.
• Commercial Launch: Positive adoption trends with nearly 300 prescribers and strong engagement from healthcare providers. Over half of prescriptions are from academic centers.
• Clinical Trials: Ongoing trials for both the RAMP 301 (confirmatory Phase III for LGSOC) and RAMP 205 (first-line pancreatic cancer) show promising results.
• New Pipeline Development: VS-7375, a KRAS G12D inhibitor, has entered clinical trials with plans for accelerated approval pathways.

3. Forward Guidance and Outlook

• Self-Sustaining Franchise: Expect the LGSOC franchise to become self-sustaining in H2 2026, with revenues from CO-PACK funding ongoing operations and trials.
• Strategic Focus for 2026: Prioritize maximizing commercial launch execution, generating data for VS-7375, and maintaining prudent capital management.

4. Bad News, Challenges, or Points of Concern

• NCCN Guidelines: Recent updates did not include recommendations for KRAS wild-type patients, which could limit treatment options for this cohort despite ongoing reimbursement success.
• Competitive Landscape: Challenges in securing coverage for off-label uses, particularly in brain and lung cancers, may impact growth.
• Financial Losses: Continued significant net losses raise concerns about long-term sustainability without additional financing.

5. Notable Q&A Insights

• NCCN Guidelines: Management expressed disappointment over the exclusion of KRAS wild-type patients but remains confident in ongoing reimbursement efforts.
• Safety Profile of VS-7375: Early data shows improved safety in the U.S. compared to China, with low rates of dose modifications and adverse events.
• Payer Coverage: Good success in securing reimbursement for KRAS wild-type patients, although some pushback noted for off-label indications.
• Future Financing: Management is exploring non-dilutive financing options and is optimistic about the potential for strategic partnerships to extend cash runway beyond 2027.

Overall, Verastem Oncology is navigating a transformative period with a solid commercial launch and promising clinical pipeline, despite facing challenges related to guideline recommendations and ongoing financial losses.